Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.

Ma, Yingjie; Yu, Junxian; Ma, Xiaoting; Li, Qin; Su, Qiang; Cao, Bangwei

Ma, Yingjie; Yu, Junxian; Ma, Xiaoting; Li, Qin; Su, Qiang; Cao, Bangwei.

Afiliación

Ma Y; Department of Oncology, Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.
Yu J; Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.
Ma X; Department of Oncology, Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.
Li Q; Department of Oncology, Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.
Su Q; Department of Oncology, Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.
Cao B; Department of Oncology, Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China.

Asia Pac J Clin Oncol ; 20(2): 180-187, 2024 Apr.

Article en En | MEDLINE | ID: mdl-37171038

Asunto(s)

Neoplasias Esofágicas; Inhibidores de Puntos de Control Inmunológico; Humanos; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Inmunoterapia/efectos adversos; Neoplasias Esofágicas/tratamiento farmacológico

Palabras clave

adverse effects; esophageal cancer; immunotherapy; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Asia Pac J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google